Health news
Low rates of treatment deintensification following a severe hypoglycemic episode suggest discordance between guidelines and practice, according to the findings of a cohort study recently published in JAMA Network Open. Although evidence-based guidelines recommend deintensification…
In an open-label, parallel-group, phase 3 trial conducted by Eli Lilly and Company, tirzepatide more effectively reduced glycated hemoglobin (HbA1C) and bodyweight compared with once-daily insulin degludec. These findings were published in The Lancet. Patients…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021